Antiglycation therapy: Discovery of promising antiglycation agents for the management of diabetic complications

References

• Ahmed N. (2005). Advanced glycation endproducts – Role in pathology of diabetic complications. Diabetes Res Clin Pract 67:3–21
   PubMed Web of Science ®Google Scholar
• Aguilar-Hernández M, Méndez JD. (2007). In vitro glycation of brain aminophospholipids by acetoacetate and its inhibition by urea. Biomed Pharmacother 61:693–7
   PubMed Web of Science ®Google Scholar
• Atta-ur-Rahman, Choudhary MI, Basha FZ, et al. (2007). Science at the interface of chemistry and biology: Discoveries of alpha-glucosidase inhibitors and antiglycation agents. Pure Appl Chem 79:2263–8
   Web of Science ®Google Scholar
• Asif M, Egan J, Vasan S, et al. (2000). An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci USA 97:2809–13
   PubMed Web of Science ®Google Scholar
• Bendayan M. (1998). Immunocytochemical detection of advanced glycation end products in rat renal tissue as a function of age and diabetes. Kidney Int 54:438–47
   PubMed Web of Science ®Google Scholar
• Cervantes-Laurean D, Schramm DD, Jacobson EL, et al. (2006). Inhibition of advanced glycation end product formation on collagen by rutin and its metabolites. J Nutr Biochem 17:531–40
   PubMed Web of Science ®Google Scholar
• Chetyrkin SV, Mathis ME, Ham AJ, et al. (2008). Propagation of protein glycation damage involves modification of tryptophan residues via reactive oxygen species: Inhibition by pyridoxamine. Free Radical Biol Med 44:1276–85
   PubMed Web of Science ®Google Scholar
• Choudhary MI, Abbas G, Ali S, et al. (2011). Substituted benzenediol Schiff bases as promising new anti-glycation agents. J Enzym Inhbi Med Chem 26:98–103
   PubMed Web of Science ®Google Scholar
• Courderot-Masuyer C, Dalloz F, Maupoil V, Rochette L. (1999). Antioxidant properties of aminoguanidine. Fundam Clin Pharmacol 13:535–40
   PubMed Web of Science ®Google Scholar
• Degenhardt TP, Fu MX, Voss E, et al. (1999). Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats. Diabetes Res Clin Pract 43:81–9
   PubMed Web of Science ®Google Scholar
• Duraisamy Y, Gaffney J, Slevin M, et al. (2003). Aminosalicylic acid reduces the antiproliferative effect of hyperglycaemia, advanced glycation endproducts and glycated basic fibroblast growth factor in cultured bovine aortic endothelial cells: Comparison with aminoguanidine. Mol Cell Biochem 246:143–53
   PubMed Web of Science ®Google Scholar
• Faustinus KY, Inteaz A, Varoujan AY, et al. (2004). Effect of limited solid-state glycation on the conformation of lysozyme by ESI-MSMS peptide mapping and molecular modeling. Bioconjugate Chem 15:27–34
   PubMed Web of Science ®Google Scholar
• Fleming TH, Theilen TM, Masania J, et al. (2013). Aging-dependent reduction in glyoxalase delays wound healing. Gerontology 59:427–37
   PubMed Web of Science ®Google Scholar
• Graves DT, Liu R, Alikhani M, et al. (2006). Diabetes-enhanced inflammation and apoptosis – Impact on periodontal pathology. J Dent Res 85:15–21
   PubMed Web of Science ®Google Scholar
• Glenis JW, Rashmi P, Helaman E, et al. (2003). DNA sequencing research group (DSRG) 2003 – A general survey of core dna sequencing facilities. J Biomol Tech 14:231–7
   Google Scholar
• Gugliucci A. (2003). A practical method to study functional impairment of proteins by glycation and effects of inhibitors using current coagulation/fibrinolysis reagent kits. Clin Biochem 36:155–8
   PubMed Web of Science ®Google Scholar
• Hadley J, Malik N, Meek K. (2001). Collagen as a model system to investigate the use of aspirin as an inhibitor of protein glycation and crosslinking. Micron 32:307–15
   PubMed Web of Science ®Google Scholar
• Harms MJ, Wilmarth PA, Kapfer DM, et al. (2004). Laser light-scattering evidence for an altered association of βB1-crystallin deamidated in the connecting peptide. Protein Sci 13:678–86
   PubMed Web of Science ®Google Scholar
• Jakug V, HrnEiarova M, Crasky J, et al. (1999). Inhibition of nonenzymatic protein glycation and lipid peroxidation by drugs with antioxidant activity. Life Sci 65:1991–3
   PubMed Web of Science ®Google Scholar
• Janani V, Kamna A, Balaram P. (2001). Helical peptide models for protein glycation: Proximity ejects in catalysis of the Amadori rearrangement. Chem Biol 8:611–25
   PubMed Web of Science ®Google Scholar
• Jianguo L, Youcai T, Qiaohua K, et al. (2012). Curcumin inhibits gene expression of receptor for advanced glycation endproducts (RAGE) in hepatic stellate cells in vitro by elevating PPARg activity and attenuating oxidative stress. Br J Pharmacol 166:2212–27
   PubMed Web of Science ®Google Scholar
• Kern TS, Engerman RL. (2001). Pharmacological inhibition of diabetic retinopathy: Aminoguanidine and aspirin. Diabetes 50:1636–42
   PubMed Web of Science ®Google Scholar
• Khalifa RG, Baynes JW, Hudson BG. (1999). Breakthroughs and view: Amadorins: Novel post-Amadori inhibitors of advanced glycation end product. Biochem Biophys Res Commun 257:251–8
   PubMed Web of Science ®Google Scholar
• Kim YS, Kim NH, Lee SW, et al. (2007). Effect of protocatechualdehyde on receptor for advanced glycation end products and TGF-beta1 expression in human lens epithelial cells cultured under diabetic conditions and on lens opacity in streptozotocin-diabetic rats. Eur J Pharmacol 569:171–9
   PubMed Web of Science ®Google Scholar
• Kislinger T, Humeny A, Peich CC, et al. (2005). Analysis of protein glycation products by MALDI-TOF/MS. Ann NY Acad Sci 1043:249–59
   PubMed Web of Science ®Google Scholar
• Lehman TD, Ortwerth BJ. (2001). Inhibitors of advanced glycation end product-associated protein cross-linking. Biochim Biophys Acta 1535:110–19
   PubMed Web of Science ®Google Scholar
• Li H, Zheng X, Wang H, et al. (2010). XLF-III-43, a novel coumarin–aspirin compound, prevents diabetic nephropathy in rats via inhibiting advanced glycation end products. Eur J Pharmacol 627:340–7
   PubMed Web of Science ®Google Scholar
• Lin RY, Choudhury RP, Cai W, et al. (2003). Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 168:213–20
   PubMed Web of Science ®Google Scholar
• Makoto S, Munetada O, Masato K. (2002). Experimental studies on the role of fructose in the development of diabetic complications. Kobe J Med Sci 48:125–36
   PubMedGoogle Scholar
• Matsuda H, Wang T, Managi H, Yoshikawa M. (2003). Structural requirements of flavonoids for inhibition of protein glycation and radical scavenging activities. Bioorgan Med Chem 11:5317–23
   PubMed Web of Science ®Google Scholar
• Matsui T, Yamagishi S, Takeuchi M, et al. (2010). Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacol Res 61:34–9
   PubMed Web of Science ®Google Scholar
• Méndez JD, Balderas FL. (2006). Inhibition by l-arginine and spermidine of hemoglobin glycation and lipid peroxidation in rats with induced diabetes. Biomed Pharmacother 60:26–31
   PubMed Web of Science ®Google Scholar
• Morais MP, Mackay JD, Bhamra SK, et al. (2010). Analysis of protein glycation using phenylboronate acrylamide gel electrophoresis. Proteomics 10:48–58
   PubMed Web of Science ®Google Scholar
• Mosihuzzman M, Naheed S, Hareem S, et al. (2013). Studies on α-glucosidase inhibition and anti-glycation potential of Iris loczyi and Iris unguicularis. Life Sci 92:187–92
   PubMed Web of Science ®Google Scholar
• Muthenna P, Akileshwari C, Reddy GB. (2012). Ellagic acid, a new antiglycation agent: Its inhibition of N-(carboxymethyl) lysine. Biochem J 442:9221–30
   Google Scholar
• Nagasawa T, Tabata N, Ito Y, et al. (2003). Inhibition of glycation reaction in tissue protein incubations by water soluble rutin derivative. Mol Cell Biochem 249:3–10
   PubMed Web of Science ®Google Scholar
• Namiki M. (2003). Advances in the Maillard reaction and glycation researches mainly on the Namiki pathway. Seikagaku 34:37–42
   Google Scholar
• Obayashi H, Nakano K, Shigeta H, et al. (1996). Formation of crossline as a fluorescent advanced glycation end product in vitro and in vivo. Biochem Biophys Res Commun 226:37–41
   PubMed Web of Science ®Google Scholar
• Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW. (2000). Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. J Biol Chem 275:21177–84
   PubMed Web of Science ®Google Scholar
• Pashikanti S, de Alba DR, Boissonneault GA, Cervantes-Laurean D. (2010). Rutin metabolites: Novel inhibitors of nonoxidative advanced glycation end products. Free Radical Biol Med 48:656–63
   PubMed Web of Science ®Google Scholar
• Pekiner B, Ulusu NN, Das-Evcimen N, et al. (2002). In vivo treatment with stobadine prevents lipid peroxidation, protein glycation and calcium overload but does not ameliorate Ca2+ -ATPase activity in heart and liver of streptozotocin-diabetic rats: Comparison with vitamin E. Biochim Biophys Acta 1588:71–8
   PubMed Web of Science ®Google Scholar
• Rahbar S, Natarajan R, Yerneni K, et al. (2000). Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 301:65–77
   PubMed Web of Science ®Google Scholar
• Sakai M, Oimomi M, Kasuga M. (2002). Experimental studies on the role of fructose in the development of diabetic complications. Kobe J Med Sci 48:125–36
   PubMedGoogle Scholar
• Shunya T, Yuko I, Yasuko K, et al. (2007). A novel inhibitor of advanced glycation and endoplasmic reticulum stress reduces infarct volume in rat focal cerebral ischemia. Brain Res 1183:124–37
   PubMed Web of Science ®Google Scholar
• Singh R, Barden A, Mori T, Beilin L. (2001). Advanced glycation end-products: A review. Diabetologia 44:129–46
   PubMed Web of Science ®Google Scholar
• Sourris KC, Harcourt BE, Forbes JM. (2009). A new perspective on therapeutic inhibition of advanced glycation in diabetic microvascular complications: Common downstream endpoints achieved through disparate therapeutic approaches. Am J Nephrol 30:323–35
   PubMed Web of Science ®Google Scholar
• Stitt AW, Gardiner TA, Duffy N, et al. (2001). Inhibition of advanced glycation/lipoxidation endproducts (AGE/ALEs) prevents retinopathy in experimental diabetes. Diabetologia 44:A290
   Google Scholar
• Suji G, Sivakami S. (2006). DNA damage by free radical production by aminoguanidine. Ann NY Acad Sci 1067:191–9
   PubMed Web of Science ®Google Scholar
• Taguchi T, Sugiura M, Hamada Y, Miwa I. (1999). Inhibition of advanced protein glycation by a Schiff base between aminoguanidine and pyridoxal. Eur J Pharmacol 378:283–9
   PubMed Web of Science ®Google Scholar
• Tan KC, Shiu SW, Chow WS, et al. (2006). Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 49:2756–62
   PubMed Web of Science ®Google Scholar
• Thomas T, Thomas TJ. (2001). Polyamines in cell growth and cell death: Molecular mechanisms and therapeutic applications. Cell Mol Life Sci 58:244–58
   PubMed Web of Science ®Google Scholar
• Vinson JA, Howard TB. (1996). Inhibition of protein glycation and advanced glycation end products by ascorbic acid and other vitamins and nutrients. J Nutr Biochem 7:659–63
   Web of Science ®Google Scholar
• Wang J, Sun B, Cao YP, Tian Y. (2009). Protein glycation inhibitory activity of wheat bran feruloyl oligosaccharides. Food Chem 112:350–3
   Web of Science ®Google Scholar
• Wolffenbuttel BHR, Boulanger CM, Crijns FRL, et al. (1998). Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 95:4630–4
   PubMed Web of Science ®Google Scholar
• Xi M, Hai C, Tang H, et al. (2008). Antioxidant and antiglycation properties of total saponins extracted from traditional Chinese medicine used to treat diabetes mellitus. Phytother Res 22:228–37
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Nakamura K, Matsui T, et al. (2008). Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: A novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs 17:98–996
   Google Scholar
• Yamaguchi F, Ariga T, Yoshimura Y, Nakazawa H. (2000). Antioxidative and anti-glycation activity of garcinol from Garcinia indica fruit rind. J Agric Food Chem 48:180–5
   PubMed Web of Science ®Google Scholar
• Yan SD, Chens X, Schmid AM, et al. (1994). Glycated tau protein in Alzheimer disease: A mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 91:7787–91
   PubMed Web of Science ®Google Scholar
• Young SK, Nan HK, Sang WL, et al. (2007). Effect of protocatechualdehyde on receptor for advanced glycation end products and TGF-β1 expression in human lens epithelial cells cultured under diabetic conditions and on lens opacity in streptozotocin-diabetic rats. Eur J Pharmacol 569:171–9
   PubMed Web of Science ®Google Scholar
• Zhang Q, Ames JM, Smith RD, et al. (2009). A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: Probing the pathogenesis of chronic disease. J Proteome Res 8:754–69
   PubMed Web of Science ®Google Scholar